Drug Profile
TQ B3233
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Centaurus Biopharma; Chia Tai Tianqing Pharmaceutical Group
- Developer Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Malignant-melanoma in China (PO, Capsule)